Stanley Druckenmiller’s Nektar Therapeutics NKTR Stock Holding History

Stanley Druckenmiller’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-66,667	Closed	-$18M	–	57
2021 Q3	$18M	Hold	66,667	–	–	0.58%	31
2021 Q2	$17.2M	Hold	66,667	–	–	0.43%	39
2021 Q1	$20M	Buy	+66,667	New	+$20.7M	0.44%	48
2020 Q1	–	Sell	-20,705	Closed	-$6.7M	–	59
2019 Q4	$6.7M	Buy	+20,705	New	+$6M	0.2%	49
2018 Q2	–	Sell	-79,487	Closed	-$127M	–	37
2018 Q1	$127M	Sell	79,487 -42,780	-35%	-$55.1M	7%	6
2017 Q4	$110M	Buy	122,267 +44,527	+57%	+$26.3M	5.52%	6
2017 Q3	$28M	Hold	77,740	–	–	1.27%	19
2017 Q2	$22.8M	Buy	77,740 +33,367	+75%	+$9.64M	1.22%	25
2017 Q1	$15.6M	Buy	+44,373	New	+$9.97M	1.02%	30
2016 Q4	–	Sell	-38,140	Closed	-$9.83M	–	53
2016 Q3	$9.83M	Buy	+38,140	New	+$9.82M	0.87%	38
2015 Q2	–	Sell	-43,667	Closed	-$7.21M	–	39
2015 Q1	$7.21M	Hold	43,667	–	–	0.92%	23
2014 Q4	$10.2M	Buy	+43,667	New	+$9.33M	1%	31

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Stanley Druckenmiller's NKTR Position: Q4 2021 in Review

Stanley Druckenmiller sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 66,667 shares — an estimated $18M sold.

Stanley Druckenmiller first reported a position in NKTR in Q4 2014 and held it in 12 quarters. The position peaked at $127M in Q1 2018. 241 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

Stanley Druckenmiller reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
Stanley Druckenmiller sold 66,667 Nektar Therapeutics shares in Q4 2021, an estimated $18M.
Stanley Druckenmiller first reported a position in Nektar Therapeutics in Q4 2014 and held it in 12 quarters.
Stanley Druckenmiller's Nektar Therapeutics position peaked at $127M in Q1 2018.
241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Duquesne Family Office's 13F filing for Q4 2021, filed 14 Feb 2022.